D. Boral Capital Reaffirms Buy Rating for Enlivex Therapeutics (NASDAQ:ENLV)

D. Boral Capital reaffirmed their buy rating on shares of Enlivex Therapeutics (NASDAQ:ENLV) in a research report released on Monday morning,Benzinga reports. The brokerage currently has a $13.00 target price on the stock.

Enlivex Therapeutics Price Performance

Shares of NASDAQ ENLV opened at $1.13 on Monday. The firm has a fifty day moving average price of $1.12 and a 200-day moving average price of $1.25. The stock has a market cap of $24.19 million, a PE ratio of -1.15 and a beta of 1.11. Enlivex Therapeutics has a 1 year low of $0.81 and a 1 year high of $4.59.

Hedge Funds Weigh In On Enlivex Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ENLV. Two Sigma Securities LLC bought a new position in shares of Enlivex Therapeutics during the fourth quarter worth $26,000. Renaissance Technologies LLC boosted its position in shares of Enlivex Therapeutics by 112.6% during the fourth quarter. Renaissance Technologies LLC now owns 158,992 shares of the company’s stock worth $186,000 after acquiring an additional 84,203 shares during the last quarter. Finally, Millennium Management LLC bought a new position in shares of Enlivex Therapeutics during the fourth quarter worth $742,000. Institutional investors own 1.02% of the company’s stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.